Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus platinum and fluoropyrimidine versus placebo plus chemotherapy in first-line advanced gastric or gastroesophageal junction adenocarcinoma
jRCT2080224723Phase 3Completed
- Sponsor
- IQVIA
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Tislelizumab plus platinum and fluoropyrimidine with Placebo plus platinum and fluoropyrimidine (2 arms). Started Jun 2019; status: completed.
02
Drugs
tislelizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2080224723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224723.